- Neuropathic pain treatments, encompassing pharmacological and non-pharmacological therapies, are increasingly vital components of chronic pain management in both hospital and outpatient settings due to their efficacy in addressing complex nerve-related conditions, improving patient quality of life, and reducing long-term healthcare costs
- The escalating demand for neuropathic pain treatments is primarily fueled by the growing prevalence of diabetes, cancer, and neurological disorders, as well as an aging global population. In addition, rising awareness and improved diagnostic capabilities are contributing to higher treatment rates and earlier intervention
- North America dominated the neuropathic pain market with the largest revenue share of 49.33% in 2024, driven by well-established healthcare infrastructure, high awareness among patients and practitioners, and a strong presence of key pharmaceutical companies
- Asia-Pacific is expected to be the fastest-growing region in the neuropathic pain market during the forecast period, with a projected CAGR of 8.4%, supported by increasing healthcare investments, expanding patient access to pain management therapies, and rising incidence of chronic conditions such as diabetes and stroke across countries such as India, China, and Japan
- The spinal cord stimulation (SCS) devices segment dominated the neuropathic pain market by type with a market share of 31.4% in 2024, owing to its effectiveness in managing chronic pain conditions unresponsive to conventional treatments, long-term cost efficiency, and increasing adoption of minimally invasive neuromodulation therapies
